Abstract
Objective
The aim of this study was to investigate the clinical value and relevance on the serum β2-microglobulin (β2-MG) of patients with thyroid cancer.
Methods
One thousand and two normal cases, 95 thyroid cancer patients and 243 nodular goiter patients were selected to measure serum β2-MG levels using double-antibody sandwich enzyme-linked immunosorbent assay (ELISA).
Results
The positive rate of 7.78% in normal population (78/1002) and 31.57% in thyroid cancer patients (30/95). There were significant differences between the normal population and thyroid cancer patients (χ 2 = 55.352; P = 0.000). The positive rate of 7.81% in nodular goiter patients (19/243) and there were no significant differences between the normal population and nodular goiter patients (χ 2 = 0.0004; P = 0.986), but significant differences between nodular goiter patients and thyroid cancer patients (χ 2 = 31.106; P = 0.000). Meanwhile, the significant difference of the positive rate existed in between the various pathological types of thyroid cancer (χ 2 = 10.015; P = 0.007), anaplastic thyroid cancer patients with the highest positive rate and The significant difference was found between the positive lymph node metastasis groups and negative lymph node metastasis groups (χ 2 = 4.441; P = 0.035), the presence of distant metastasis group and absence of distant metastasis group (χ 2 = 9.795; P = 0.002).
Conclusion
Serum β2-MG levels and prognosis of thyroid cancer patients was negatively correlated. It showed important clinical value to detect the level of β2-MG in the early diagnosis, prognosis and the clinical observation for thyroid cancer patients.
References
Cao MG, Auge JM, Molina R, et al. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res, 2007, 27: 595–599.
Chinese Medical Association. Clinical guidelines for diagnosis and treatment (tumors section). Beijing: People’s Medical Publishing House, 2005. 46–52.
Du HF, Li KS, Lian XW, et al. Production and identification of monoclonal antibodies against β2-microglobulin. Chin Med Her (Chinese), 2008, 4: 36–37.
Josson S, Nomura T, Lin JT, et al. β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res, 2011, 71: 2600–2610.
Yang C, Lan TB, Cheng Y. Renal impairment in multiple myelomas. Chinese-German J Clin Oncol, 2011, 10: 418–422.
Chen CH, Su CY, Chien CY, et al. Overexpression of beta2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br J Cancer, 2008, 99: 1453–1461.
Nomura T, Huang WC, Seo S, et al. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol, 2007, 178: 292–300.
Liu QJ, Tian YX, Li HP. Correlativity of lymph node micrometastases detection in follicular carcinoma of thyroid in different risk groups. Chinese-German J Clin Oncol, 2009, 8: 699–701.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ma, S., Liu, Q. & Li, K. The clinical significance evaluation of serum β2-microglobulin for thyroid cancer patients. Chin. -Ger. J. Clin. Oncol. 11, 271–273 (2012). https://doi.org/10.1007/s10330-012-0960-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-012-0960-6